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ABSTRACT
Purpose. To evaluate the trend in the use of primary
endocrine treatment (PET) for elderly patients with oper-
able breast cancer and to study mean time to response
(TTR), local control, time to progression (TTP), and
overall survival.
Methods. Data of 184 patients aged C75 years, diagnosed
with breast cancer in the south of the Netherlands between
2001 and 2008 and receiving PET, were analyzed.
Results. The percentage of women C75 years with breast
cancer receiving PET in the south of the Netherlands
decreased from 23% in the period 1988–1992 to 12% in
1997–2000, and increased to 29% in 2005–2008. Mean age
at diagnosis of 184 patients treated with PET in the period
2001–2008 was 84 years (range 75–89 years). Mean length
of follow-up was 2.6 years. In 107 patients (58%), an ini-
tial response was achieved (mean TTR 7 months), 21
patients (12%) showed stable disease. A total of 64 patients
(35%), with or without prior response, eventually displayed
progression (mean TTP 20 months). No differences in TTR
and TTP were observed between the patients starting with
tamoxifen or an aromatase inhibitor. One hundred nineteen
(65%) of 184 patients had died by January 1, 2010. In 17
patients (14%), breast cancer was the cause of death.
Conclusions. Tumor progression was observed in a sub-
stantial proportion of the cohort, but only a small number
of patients died of breast cancer. Further research is needed
on the safety and effectiveness of PET for elderly women
with breast cancer to justify the current widespread use.
Theoptimaltreatmentofelderlywomenwithbreastcancer
is difﬁcult to deﬁne. Several studies have shown that elderly
women with breast cancer are less likely to receive what is
consideredstandardbreastcancertreatmentcomparedtotheir
younger counterparts. They are less likely to be treated with
surgery and, if treated with surgery, are less likely to undergo
breastconservingsurgeryandaxillarylymphnodedissection.
They are also less likely to receive radiotherapy after breast-
conserving surgery.
1–4 Reasons given for the decision to
refrain from standard local therapy in elderly breast cancer
patients are comorbidity, patient preferences, reduced func-
tional and mental status, and slowly progressive disease
requiringlessintensivetreatment.
5–7Asanalternativetolocal
therapy, physicians relatively often use tamoxifen or an aro-
matase inhibitor (AI) as the sole treatment for their elderly
patients.
5 The knowledge that most of the tumors in elderly
breast cancer patients are estrogen and/or progesterone
receptorpositiveexplainswhythisprimaryendocrinetherapy
(PET) is considered an attractive treatment option.
8,9
PET has been studied in several randomized controlled
trials, all comparing the use of tamoxifen alone to surgery
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breast cancer. In a Cochrane review by Hind et al., based
on seven randomized controlled trials involving 1446
elderly women unselected for estrogen receptor status,
tamoxifen alone was proven inferior with respect to local
control compared to surgery plus endocrine therapy (haz-
ard ratio 0.28, 95% conﬁdence interval [CI] 0.23–0.35).
However, no statistically signiﬁcant difference in overall
survival was found when surgery was avoided.
10 On the
basis of the inferior local control rate observed in this
review, the use of tamoxifen as PET for elderly patients
was discouraged and surgery was recommended, provided
that the patient is ﬁt for surgery.
AIs have only been studied in the (neo)adjuvant setting,
where they seem to be superior to tamoxifen regarding
local tumor response.
11–14 On the basis of these results, it
may be assumed that AIs are also more effective than
tamoxifen when used as PET. So far, to our knowledge, no
data are available to support this assumption. We think that
the number of elderly patients receiving PET has increased
since the introduction of AIs. Therefore, the aims of the
present study were to analyze the trend in the use of PET in
elderly breast cancer patients in the southeast of the
Netherlands over the last decade and to compare the local
control rates between users of AIs and tamoxifen.
METHODS
Patients
Trends in the use of PET were studied by using data
from the Eindhoven Cancer Registry (ECR), which is a
population-based registry serving a population of approx-
imately 2.4 million inhabitants in the southern part of the
Netherlands. Data were used from all patients aged
75 years or older who were diagnosed with breast cancer
during 1988–2008. To collect additional information from
clinical records, 223 breast cancer patients aged 75 years or
older were selected who were treated with PET in 4 of the
10 hospitals covered by the ECR in the period 2001–2008.
These hospitals were selected because of their vicinity to
the hospital of the principal investigator (C.J.W.), thus
facilitating data collection. These 223 patients represent
40% of all patients treated with PET in the ECR region in
that period. The clinical records of all 223 patients were
reviewed to collect detailed information regarding clinical
stage at diagnosis, histopathology of the tumor, hormone
receptor status, reason or reasons for choosing PET instead
of surgery, local tumor response, local progression of dis-
ease, and date and cause of death. Family physicians and
nursing home physicians were contacted, if possible, in
case of missing follow-up data. January 1, 2010, was
considered the end of the follow-up period. After exami-
nation of the clinical records, 39 patients were excluded: 34
patients had metastatic disease at diagnosis, two patients
had already been receiving endocrine therapy before a
histological diagnosis of breast cancer was made, one
patient was male, one patient had also received chemo-
therapy within a week after initiating PET, and one patient
had received radiofrequency ablation before the start of
PET. After exclusion of these patients, 184 patients
remained available for the analyses.
Statistical Analyses
Trends in the use of PET in the period 1988–2008 were
studied by calculating the proportion of all patients with
breast cancer receiving PET for all separate years of
diagnosis and statistical signiﬁcance was tested by the
Mantel–Haenszel Chi-square test.
For the selected cohort of 184 patients we collected
information on their local tumor response to PET (initial
decrease of tumor size, stable disease, and local progres-
sion), as conﬁrmed by physical examination or breast
imaging. We calculated the time to complete or partial
local response (TTR) or time to progression (TTP) after
PET. Information was also collected on the date and cause
of death. Time until these end points was calculated from
the date of start of PET. Survival was calculated from the
time of diagnosis until death or January 1, 2010. A Kaplan–
Meier analysis with a log rank test was used to calculate
overall and 5-year survival. Survival of the 184 patients
receiving PET, with or without delayed surgery, in the
period 2001–2008 was compared with the survival of all
patients aged 75 years or older who received primary
surgery in the south of the Netherlands in the same period
(n = 1504).
RESULTS
Trends in the Use of PET
During 1988–2008, a total of 4650 patients C75 years
were diagnosed with breast cancer in the south of the
Netherlands. Of these, 3510 (75.5%) received surgery as
primary treatment, and 946 (20.3%) were treated with PET.
When analyzing the use of PET over the years, a biphasic
trend was observed (Fig. 1). Between 1988 and 1992, 23%
of the women 75 years or older in the southeast of the
Netherlands received PET. This percentage decreased to
12% in the period 1997–2000 (P\0.001), followed by an
increase to 29% in the period 2005–2008 (P = 0.001). The
percentage of elderly breast cancer patients treated with
PET varied from 9% to 44% between hospitals between
1186 C. J. Wink et al.1988 and 2008. The prescribed type of PET varied over the
years. In the studied cohort, most patients received
tamoxifen until 2004. From 2005 onward, AIs were pre-
scribed to 60–70% of the patients receiving PET (Fig. 2).
Patient Characteristics
Details of the 184 patients of whom the clinical records
were examined are presented in Table 1. The mean age at
diagnosis of the primary tumor was 84 years (range
75–89 years). Most tumors were invasive ductal carcino-
mas (n = 115, 63%). Hormone receptor status was not
known for 16.3% of the patients, either because patients
refused a histological biopsy, or because only a ﬁne-needle
biopsy was performed or insufﬁcient material was obtained
by large-core needle biopsy. Nine patients (5%) with a
negative hormone receptor status (deﬁned as a receptor
positivity of less than 10%) received PET.
One hundred one patients (55%) were treated with
tamoxifen as the initial therapy, 82 patients initiated
FIG. 1 Percentage of patients aged C75 years with breast cancer
receiving primary endocrine treatment in the south of the Netherlands
in the period 1988–2008 by year of diagnosis
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FIG. 2 Type of endocrine treatment for the studied cohort of 184
patients C75 years with breast cancer treated with primary endocrine
treatment in the south of the Netherlands in the period 2001–2008 by
year of diagnosis
TABLE 1 Characteristics of 184 patients aged C75 years who
received PET in the south of the Netherlands between 2001 and 2008
Characteristic n %
Clinical tumor status (cT)
1 55 29.8
2 94 51.1
3 3 1.6
4 27 14.7
Unknown 5 2.7
Clinical nodal status (cN)
Positive 41 22.3
Negative 129 70.1
Unknown 14 7.6
Histological type of primary tumor
a
Invasive ductal 115 62.5
Invasive lobular 27 14.7
Other 7 3.8
Unknown 35 19.0
Estrogen receptor status
a
Positive 145 78.8
Negative 9 4.9
Unknown 30 16.3
Progesterone receptor status
a
Positive 117 63.6
Negative 37 20.1
Unknown 30 16.3
HER2 status
a
Positive 4 2.2
Negative 66 35.9
Unknown 114 62.0
No. of comorbidities
0 16 8.7
1 51 27.7
2 41 22.3
3 42 22.8
C4 24 13.0
First-line endocrine agent
Tamoxifen 101 54.9
AI 82 44.6
Letrozole (Femara) 30 16.3
Anastrozole (Arimidex) 39 21.2
Exemestane (Aromasin) 13 7.1
Unknown 1 0.5
a Information derived from ﬁne-needle aspiration biopsy
Hormone Treatment for Operable Breast Cancer 1187therapy with an AI (45%), and for one patient, the type of
endocrine therapy was not known. Several reasons to pre-
scribe PET instead of performing surgery were mentioned
in the clinical records. In 65 patients, the treating physician
declared the presence of comorbidities to be a reason for
omitting surgery, and in 27 patients, age was considered
to be an important reason to opt for PET. Seventy-six
patients were reported to have chosen PET over surgery
themselves.
Response and TTP
In 107 patients (58%), an initial response (partial
regression or complete clinical response of the primary
tumor) was observed at physical examination by the
responsible physician. In 62 (58%) of these 107 patients,
this local response was conﬁrmed by breast imaging
(mammogram or breast ultrasound). The average ± stan-
dard deviation time to response (TTR) after initiating PET
was 7 ± 5 months. In 21 patients (11%), the tumor
remained locally stable after initiating PET (no regression
or progression). Twenty-four patients (13%) had local
disease progression without an initial local response, and
40 (37%) of the 107 patients with an initial response to the
PET eventually showed local progression. Thus, a total of
64 patients (35%) eventually experienced local progression
of their disease despite endocrine therapy. The aver-
age ± standard deviation TTP after starting PET was
20 ± 17 months). In 38 patients, the local progression
resulted in a switch to another hormone therapy, and 7
patients received rescue surgery. Two patients received no
other treatment, 2 had radiofrequency ablation, 1 had
chemotherapy, 6 continued to receive endocrine treatment
until their death, and 4 patients were still receiving endo-
crine treatment by the end of the follow-up period. For 4
patients, information on treatment after local progression
was not available. Eventually, 8 of the 38 patients who
switched to another hormone therapy after local tumor
progression also needed to undergo surgery. Other reasons
to switch or stop the initial treatment, besides progression
of disease, were adverse effects of PET, lack of tumor
regression, or to prevent progression after a certain time.
By the end of the follow-up period, 22 (12%) of 184
patients had undergone surgery, and 54 patients (29%) had
switched to another hormone agent. Of the 22 patients who
started with PET and eventually underwent surgery, 6
developed a local recurrence after surgery.
Tamoxifen versus AIs
The mean length of follow-up was 3.0 years for patients
who received tamoxifen, versus 2.2 years for the patients
receiving an AI (P = 0.006). The Kaplan–Meier analysis
revealed no signiﬁcant difference in TTR (P = 0.487) or
TTP between both groups (P = 0.498; Fig. 3).
Survival
The mean length of follow-up from diagnosis for all 184
patients was 2.6 years (range 0.08–8.48 years). By the end
of the follow-up period, 119 patients (65%) had died. In 17
of these patients (14%), breast cancer was the cause of
death. For 32 patients the cause of death could not be
retrieved and 70 patients (59%) died of non-breast-cancer-
related causes.
The 5-year overall survival of the patients receiving PET
was 27% (95% CI 19.1–34.8), versus 62.3% (95% CI
FIG. 3 TTP of 184 patients aged C75 years who received primary
endocrine treatment in the period 2001–2008 in the south of the
Netherlands: tamoxifen compared to aromatase inhibitors (AIs)
FIG. 4 Overall survival of 184 patients aged C75 years who
received primary endocrine treatment in the period 2001–2008 in
the south of the Netherlands vs. all patients aged C75 years treated
with primary surgery in the same region and time period (n = 1504)
1188 C. J. Wink et al.59.4–65.2) for the breast cancer patients C75 years in the
south of the Netherlands treated primarily with surgery
(with or without adjuvant treatment) during the same per-
iod (Fig. 4). Age and prevalence of comorbidity differed
signiﬁcantly between the two groups: the patients treated
with surgery were younger and had signiﬁcantly less
comorbidities (Table 2).
DISCUSSION
Our analysis of data retrieved from the ECR showed a
biphasic trend in the use of PET in the south of the
Netherlands over the last two decades, with an initial
decrease followed by a sharp increase again after 1999.
This is a remarkable ﬁnding, considering the described
inferiority of tamoxifen compared to surgery with regard to
local control and the lack of evidence-based data con-
cerning local control and survival with monotherapy with
AI in the literature. We cannot give a deﬁnitive explanation
for this trend, but we hypothesize that the initial downward
trend may be the effect of the growing evidence for the
inferiority of tamoxifen compared to surgery with respect
to local control appearing between 1988 and 1998.
15–18
This may have caused physicians to be hesitant to prescribe
PET, out of fear for the development of irresectable local
disease. The arrival of the AIs, with good clinical results in
the (neo)adjuvant setting, may have reduced this fear and
could explain the rise in the use of endocrine therapy as
primary treatment for elderly breast cancer patients from
2000 onward.
11–14 This hypothesis is supported by our
ﬁnding that the use of AIs, compared to tamoxifen, has
increased over the last couple of years (Fig. 2). To date, no
successful research on the effectiveness and safety of
monotherapy with AIs has been performed in elderly
women with breast cancer. Several studies have failed—for
example, the ESTEeM (Endocrine ? Surgical Therapy
for Elderly women with Mammary cancer) trial.
This multicenter randomized trial in the UK planned to
compare surgery with adjuvant anastrozole versus primary
anastrozole in 1200 women aged C75 years with estrogen
receptor–positive, early operable primary breast cancer.
Unfortunately, unsatisfactory recruitment caused the trial
to be closed prematurely.
19
Not only in the south of the Netherlands but also in other
parts ofEurope,asubstantialnumberof elderly women with
breastcancerarereceivingPET.
5,20Wyldetal.reported40%
of the women C70 years were receiving PET for breast
cancer in the UK in 2002.
5 We found large differences
between hospitals in the percentage of elderly breast cancer
patients treated with PET in the south of the Netherlands,
indicating that there is a lack of consensus between physi-
cians with respect to its use. Such lack of consensus is also
apparent in the UK, where data from the Breast Cancer
ClinicalOutcomeMeasures Report showed that nonsurgical
treatment rates vary 11–40% between hospitals in women
aged C70 years.
21 The widespread use of PET, the large
variationinprescriptionratesbetweenhospitals,andthelack
of evidence for the safety and effectiveness emphasize the
needforrandomizedstudiesonAI,orPETingeneral,among
elderly women. Survival in our cohort was signiﬁcantly
compromised, as compared to the group primarily treated
with surgery (P\0.001). This result is difﬁcult to interpret
because of the nonrandomized study design. At least it
indicatesthatPETwasgenerallyreservedforpatientsinpoor
physical condition, as was expressed by the large difference
in age and comorbidity between the two groups. Comor-
biditywasalsomentionedinthemedicalﬁlesasanimportant
reason to choose PET instead of surgery. This ﬁnding on the
role of comorbidity is consistent with previous studies
addressing the inﬂuence of comorbidity on treatment deci-
sions and survival for elderly patients with breast cancer.
For example, Louwman et al. described that patients aged
80 years or older were less often treated with optimal sur-
gery alone in the presence of comorbidity (21% vs. 26%,
P = 0.09) and more often treated with tamoxifen only (21%
vs. 14%, P = 0.01).
22 Satariano et al. observed an overall
association between comorbidity and type of breast cancer
treatment (P\0.001).
23
The meta-analysis by Hind et al. showed no difference
in overall survival between women treated with tamoxifen
only and women treated with surgery with or without
adjuvant tamoxifen.
10 Only one of the included random-
ized controlled trials showed an advantage in survival for
surgery with adjuvant endocrine therapy. In a randomized
trial by Fennessy et al., an overall 5-year survival of 67%
was observed after surgery with adjuvant tamoxifen versus
59.5% after tamoxifen only.
24
Because of the retrospective design of our study, quality
of life was not assessed. Given the limited life expectancy
of these older patients, quality of life may be at least as
TABLE 2 Age and comorbidity of patients aged C75 years who
received surgery or PET for breast cancer in the south of the Neth-
erlands between 2001 and 2008
Characteristic Treatment P value
Surgery (n = 1504) PET (n = 184)
n % n %
Mean age, y 80.2 83.8 \0.001
No. of comorbidities \0.001
0 325 21.6 16 8.7
1 448 29.8 51 27.7
C2 574 38.2 107 58.2
Unknown 157 10.4 10 5.4
Hormone Treatment for Operable Breast Cancer 1189important as the potential survival gain associated with the
different treatment options. Several other limitations also
relate to the retrospective study design, such as residual
confounding when comparing the results of the different
treatment options. Performance status, social support, and
therapy compliance are examples of potential sources of
such residual confounding, especially in the elderly.
The gathering of long-term follow-up information of
elderly patients was challenging for several reasons.
Medical ﬁles of some patients who had died had already
been destroyed, and in some of these cases, information
could not be obtained from their family physicians.
Moreover, not all family physicians or nursing home
physicians could be reached, and some of them refused to
participate. This may have caused an underestimation of
the number of patients with disease progression. Because
this was a retrospective study, patients were not evaluated
at set times during their treatment. Therefore, it is possible
that initial treatment responses had been missed and only
progression was recorded properly in the medical ﬁle.
Survival data were obtained from the cancer registry and
were complete. However, the cause of death remained
uncertain for 32 patients (17.4%). We cannot think of any
reason why the distribution of the causes of death for these
patients would have been different than for the patients for
whom the cause of death was known.
In conclusion, survival in our group of patients treated
with PET was compromised compared to the patients
C75 years treated with primary surgery in the same period.
This was probably due to differences in age and comor-
bidity at baseline, causing the physicians to choose a
different treatment modality. The fact that most of the
patients in our group died of other causes than breast
cancer supports those treatment choices. However, the
deﬁnite role of PET in the management of breast cancer in
the elderly needs to be further assessed. There is still a lack
of evidence to justify the current widespread use of PET as
primary therapy for elderly women with breast cancer. PET
for breast cancer should be limited to the frail older patient
who is unﬁt for surgery. Further research is needed, par-
ticularly in the areas of improved identiﬁcation of the frail
patient and the safety, quality of life, and effectiveness of
monotherapy with AIs.
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